119 results found
    1. Cancer Biology
    2. Genetics and Genomics

    Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction

    Shixiang Wang et al.
    Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.
    1. Cancer Biology

    Cancer Immunotherapy: A peptide puzzle

    Jian Guan, Nilabh Shastri
    Why does cancer develop in situations where the immune system is perfectly capable of eliminating it?
    Insight
    Available as:
    • HTML
    • PDF
    1. Cancer Biology
    2. Immunology and Inflammation

    The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy

    Aaron R Lim et al.
    Diverse components of the tumor microenvironment affect T cell metabolism in ways that are crucial to improving immunotherapy.
    1. Immunology and Inflammation

    Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy

    Alok Kumar et al.
    Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.
    1. Cancer Biology
    2. Immunology and Inflammation

    SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint

    Emma Hajaj et al.
    SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.
    1. Cancer Biology
    2. Immunology and Inflammation

    Domain-swapped T cell receptors improve the safety of TCR gene therapy

    Michael T Bethune et al.
    Engineered T cell receptors enable targeted immunotherapy with a reduced risk of harmful autoimmunity.
    1. Cancer Biology
    2. Immunology and Inflammation

    Cancer systems immunology

    Nathan E Reticker-Flynn, Edgar G Engleman
    Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.
    1. Cancer Biology

    T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

    Marta Canel et al.
    Cancer cell expression of the T-cell co-stimulatory molecule CD80, or treatment with agonistic antibodies targeting the T-cell co-stimulatory receptors OX-40 or 4-1BB, enhances the anti-tumor activity of FAK inhibition.
    1. Cancer Biology
    2. Genetics and Genomics

    Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression

    Yiu Huen Tsang et al.
    An unrecognized regulation on MAGEA protein stability promotes pancreatic cancer progression via manipulating autophagy and may impact the clinical utility of MAGEA-targeted immunotherapy.
    1. Cancer Biology

    Cancer Risk: Why do women with melanoma do better than men?

    Keiran SM Smalley
    Harnessing female sex hormones may improve how all patients with melanoma respond to treatment.
    Insight
    Available as:
    • HTML
    • PDF

Refine your results by:

Type
Research categories